Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Pseudolaric Tincture is a topical antifungal medication widely used in Traditional Chinese Medicine and modern dermatology in China. Developed and manufactured by Henan Purui Pharmaceutical, this formulation typically consists of extracts from *Cortex Pseudolaricis* (the root bark of *Pseudolaris kaempferi*), combined with benzoic acid and salicylic acid. The primary active constituent, pseudolaric acid B, exerts potent antifungal effects by binding to the colchicine site of tubulin, thereby inhibiting microtubule polymerization and disrupting fungal cell division. Salicylic acid serves as a keratolytic agent, softening the stratum corneum to enhance the penetration of the antifungal components, while benzoic acid provides additional antiseptic and antifungal properties. It is indicated for the treatment of various superficial fungal skin infections, including tinea pedis (athlete's foot), tinea corporis (ringworm), and tinea cruris (jock itch).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound pseudolaric tincture.